Aromatic-cationic peptides and methods for using same
AssigneesMayo Foundation for Medical Education and Research, Stealth Peptides International, Inc.
InventorsD. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
Claims83
A method for treating atherosclerotic renal artery stenosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating atherosclerotic renal artery stenosis in a subject in need thereof, the method comprising performing percutaneous transluminal renal angioplasty on the subject and administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating contralateral kidney injury associated with unilateral or bilateral athlerosclerotic renal artery stenosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating congestive heart failure associated with atherosclerotic renal artery stenosis in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating atherosclerotic renal vascular disease (ARVD) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating impaired renal hemodynamics caused by atherosclerotic renal artery stenosis (ARAS) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.
A method for treating impaired renal hemodynamics caused by atherosclerotic renal artery stenosis (ARAS) in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide D-Arg-2′,6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof in conjunction with one or more antihypertensive agents.
Dependencies are inferred from the claim text.